Co-inhibition of adenosine generation and signalling: a new combination cancer therapy

腺苷生成和信号传导的共同抑制：一种新的组合癌症疗法

• 批准号: nhmrc : 1120887
• 负责人: A/Pr Michele Teng
• 金额: $ 40.12万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/co-inhibition-adenosine-cancer-therapy/946639
• 关键词: Co; inhibition; adenosine; generation; signalling

Cancer is a major killer of Australians and there is a need to develop new combination therapies that halt cancer growth and spread. A metabolic product of the cancer called adenosine can be exploited by several different treatment approaches. Surprisingly we have found that both preventing adenosine generation and its effects on immune cells can together more effectively slow tumour growth and spread. If we can better understand why, this approach can be quickly brought it to clinical practice.

癌症是澳大利亚人的主要杀手，需要开发新的联合疗法来阻止癌症生长和扩散。癌症的代谢产物腺苷可以通过多种不同的治疗方法来利用。令人惊讶的是，我们发现防止腺苷生成及其对免疫细胞的影响可以更有效地减缓肿瘤的生长和扩散。如果我们能够更好地理解其中的原因，这种方法就可以很快地将其应用于临床实践。